Terms: = Skin cancer AND PR, PGR, progesterone receptor AND Prognosis
92 results:
1. Case report: A case of Paget disease outside the axillary breast.
Zhou Z; Zhou B; Wu X; Wei W
Medicine (Baltimore); 2024 Mar; 103(13):e37541. PubMed ID: 38552095
[TBL] [Abstract] [Full Text] [Related]
2. A case report and literature review on a rare subtype of triple-negative breast cancer in children.
Shi L; Zhang Y; Wu J; Li J; Zhu J; Xu Y; Li N; Li Q; Zhang W
BMC Pediatr; 2023 Sep; 23(1):494. PubMed ID: 37773118
[TBL] [Abstract] [Full Text] [Related]
3. The prognostic significance of skin involvement in breast cancer patients with chest wall recurrence.
Zhou D; Li M; Xu F; Zheng Q; Lu Q; Hong R; Wang S
Ann Med; 2023 Dec; 55(1):2232299. PubMed ID: 37431586
[TBL] [Abstract] [Full Text] [Related]
4. Socioeconomic status and cancer survival in Brazil: Analysis of population data from the municipalities of Aracaju and Curitiba, 1996-2012.
Renna Junior NL; Azevedo E Silva G
Cancer Epidemiol; 2023 Aug; 85():102394. PubMed ID: 37419053
[TBL] [Abstract] [Full Text] [Related]
5. [Clinical Analysis of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang QX; Wang LL; Guan J; Zhou Y; Zhang T; Su F; Chen LQ; Cao Y; Cheng H; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):896-901. PubMed ID: 37356957
[TBL] [Abstract] [Full Text] [Related]
6. Low-grade adenosquamous carcinoma of the breast: A rare case presentation.
Abrari A; Shehwar D; Akhtar K
J Cancer Res Ther; 2023; 19(2):480-483. PubMed ID: 37313920
[TBL] [Abstract] [Full Text] [Related]
7. A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition.
Buchbinder EI; Giobbie-Hurder A; Ott PA
Invest New Drugs; 2023 Jun; 41(3):365-370. PubMed ID: 37097370
[TBL] [Abstract] [Full Text] [Related]
8. Anti-PD-1 immunotherapy with dose-adjusted ultra-hypofractionated re-irradiation in patients with locoregionally recurrent head and neck cancer.
Koukourakis IM; Giakzidis AG; Koukourakis MI
Clin Transl Oncol; 2023 Oct; 25(10):3032-3041. PubMed ID: 37059932
[TBL] [Abstract] [Full Text] [Related]
9. [Eight Cases of Breast cancer That Relapsed More Than Ten Years after Initial Treatment].
Yoshimura A; Ueda T; Tanaka T; Kirihataya Y; Soga M; Yokotani T
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1935-1937. PubMed ID: 36733049
[TBL] [Abstract] [Full Text] [Related]
10. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Reiswich V; Schmidt CE; Lennartz M; Höflmayer D; Hube-Magg C; Weidemann S; Fraune C; Büscheck F; Möller K; Bernreuther C; Simon R; Clauditz TS; Blessin NC; Bady E; Sauter G; Uhlig R; Steurer S; Minner S; Burandt E; Dum D; Marx AH; Krech T; Lebok P; Hinsch A; Jacobsen F
Pathobiology; 2023; 90(4):219-232. PubMed ID: 36649695
[TBL] [Abstract] [Full Text] [Related]
11. Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.
Tanaka T; Inamoto Y; Ito A; Watanabe M; Takeda W; Aoki J; Kim SW; Fukuda T
Hematol Oncol; 2023 Aug; 41(3):389-395. PubMed ID: 36513602
[TBL] [Abstract] [Full Text] [Related]
12. Differences of Clinicopathological Features between Metaplastic Breast Carcinoma and Nonspecific Invasive Breast Carcinoma and Prognostic Profile of Metaplastic Breast Carcinoma.
Qiu Y; Chen Y; Zhu L; Chen H; Dai Y; Bao B; Tian L; Hao X; Wang J
Breast J; 2022; 2022():2500594. PubMed ID: 36051469
[TBL] [Abstract] [Full Text] [Related]
13. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
[TBL] [Abstract] [Full Text] [Related]
14. Diet quality is associated with primary melanoma thickness.
Hughes MCB; Malt M; Khosrotehrani K; Smithers BM; Green AC
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1745-1750. PubMed ID: 35462440
[TBL] [Abstract] [Full Text] [Related]
15. Electrochemotherapy as palliative treatment in patients with recurrent and/or metastatic head and neck tumours: features analysis for an early determination of the partial responsive patients.
Maglitto F; Salzano G; Longo F; Di Bernardo E; D'Alessio V; Fusco R; Aversa C; Pavone E; Pontone M; Marciano ML; Togo G; De Fazio GR; Ordano D; Maglione MG; Vaira LA; Bergonzani M; Salzano FA; Maiolino P; Califano L; Ionna F; Perri F
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1350-1363. PubMed ID: 35253191
[TBL] [Abstract] [Full Text] [Related]
16. A pre-operative prognostic model predicting all cause and cause specific mortality for women presenting with invasive breast cancer.
Wang H; Donnan P; Macaskill EJ; Jordan L; Thompson A; Evans A
Breast; 2022 Feb; 61():11-21. PubMed ID: 34891035
[TBL] [Abstract] [Full Text] [Related]
17. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
Hamid O; Robert C; Daud A; Carlino MS; Mitchell TC; Hersey P; Schachter J; Long GV; Hodi FS; Wolchok JD; Arance A; Grob JJ; Joshua AM; Weber JS; Mortier L; Jensen E; Diede SJ; Moreno BH; Ribas A
Eur J Cancer; 2021 Nov; 157():391-402. PubMed ID: 34571336
[TBL] [Abstract] [Full Text] [Related]
18. [Clinicopathological features of malignant mixed mesodermal tumor: analysis of 50 cases].
Ding XH; Ma ZY; Wang YF; Dou FX; Yuan J; Tian X; Liu AJ
Zhonghua Bing Li Xue Za Zhi; 2021 Sep; 50(9):1008-1013. PubMed ID: 34496490
[No Abstract] [Full Text] [Related]
19. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
Mulder EEAP; de Joode K; Litière S; Ten Tije AJ; Suijkerbuijk KPM; Boers-Sonderen MJ; Hospers GAP; de Groot JWB; van den Eertwegh AJM; Aarts MJB; Piersma D; van Rijn RS; Kapiteijn E; Vreugdenhil G; van den Berkmortel FWPJ; Hoop EO; Franken MG; Ryll B; Rutkowski P; Sleijfer S; Haanen JBAG; van der Veldt AAM
BMC Cancer; 2021 Mar; 21(1):323. PubMed ID: 33765967
[TBL] [Abstract] [Full Text] [Related]
20. Effect of osimertinib in treating patients with first-generation EGFR-TKI-resistant advanced non-small cell lung cancer and prognostic analysis.
Yang Y; Guo Y; Wang R; Li J; Zhu H; Guo RTW
J BUON; 2021; 26(1):51-57. PubMed ID: 33721431
[TBL] [Abstract] [Full Text] [Related]
[Next]
